Serum Enzyme Testing Emerges as a Diagnostic Tool in Ischemic Heart Disease
In 1963, serum enzyme levels sat at the center of an important diagnostic problem: how to identify ischemic heart disease from blood alone, before electrocardiography, symptoms, and bedside examination could be fully trusted to settle the question. The article by N H Martin in J Clin Pathol addressed that problem directly, at a time when clinicians were increasingly looking to biochemical injury markers to help distinguish myocardial injury from other causes of chest pain and systemic illness.
The clinical appeal is easy to understand. When heart muscle is injured, intracellular enzymes can escape into the circulation. A rise in serum enzyme activity offers a biochemical footprint of tissue damage, and in the era before modern cardiac-specific biomarkers, that footprint carried real diagnostic weight. The paper’s indexing around aspartate aminotransferases and lactate dehydrogenase reflects the main laboratory candidates of that period, enzymes that could be measured in blood and interpreted as indirect evidence of organ injury.
A single abnormal enzyme result could not define the entire syndrome of ischemic heart disease, but it could alter the diagnostic frame within hours rather than days.
Why Enzyme Leakage Mattered in the Pre-Troponin Era
The biological logic behind serum enzyme testing is straightforward. Ischemia severe enough to damage myocardial cells disrupts membrane integrity, allowing cytosolic and mitochondrial constituents to enter the bloodstream. Enzymes such as AST and LDH are not heart-specific, yet their appearance in serum provided one of the earliest laboratory pathways to detect acute cellular injury. In practice, that meant a patient with chest discomfort could be assessed not only through symptoms and tracings, but also through the body’s biochemical response to injury.
This matters because ischemic heart disease is not a single phenotype. Acute infarction, transient ischemia, and chronic coronary insufficiency can overlap clinically. Enzyme assays offered a way to move beyond impressionistic diagnosis and toward a more objective signal of myocardial damage. Even so, the limitations were substantial. Many enzymes rise in liver, skeletal muscle, and other tissues, and that lack of specificity created interpretive uncertainty. A raised serum enzyme pattern could support cardiac injury, but it could not stand alone as proof of coronary disease.
The article’s subject sits in that tension between promise and ambiguity. Laboratory medicine was beginning to supply clinicians with markers of tissue necrosis, yet the markers available in the early 1960s were blunt instruments compared with contemporary cardiac biomarker panels.
Aspartate Aminotransferase and Lactate Dehydrogenase as Early Cardiac Clues
Among the enzymes indexed with the paper, aspartate aminotransferase and lactate dehydrogenase were central to mid-century diagnostic strategies. AST could rise after myocardial injury, but it also reflected hepatic and skeletal muscle damage, making interpretation dependent on the broader clinical picture. LDH offered another route to detecting tissue injury, and its patterns were studied for their diagnostic utility in coronary syndromes. Those two markers represented an important step in the evolution of cardiac laboratory medicine: not yet cardiac-specific, but more informative than symptoms alone.
Their use also reveals how diagnosis was becoming biochemical. Clinicians were no longer relying solely on whether a patient had crushing chest pain or a suggestive electrocardiogram. They were asking whether the bloodstream contained evidence of necrosis, whether the enzyme profile fit the timing of the event, and whether serial testing could separate evolving infarction from older, unrelated disease. That approach laid the groundwork for later biomarker logic, including the serial rise-and-fall pattern that eventually became central to cardiac troponin interpretation.
What the 1963 Paper Represents Clinically
The value of this paper lies not in a modern endpoint or a randomized comparison, but in its place in the historical transition from bedside diagnosis to laboratory-supported cardiology. By focusing on serum enzyme levels, Martin’s work participated in a larger effort to make ischemic heart disease measurable in biological terms. That shift had consequences for triage, prognosis, and the timing of intervention, even before reperfusion therapies transformed acute coronary care.
The paper also reminds clinicians how much diagnostic medicine depends on assay quality. An enzyme test is only as useful as the specificity of the enzyme, the timing of sampling, and the clinical context in which the value is read. A sample drawn too early may miss the rise. A sample drawn too late may obscure the acute event. A value influenced by non-cardiac tissue damage may mislead. Those constraints defined the early era of enzyme diagnosis and explain why enzyme testing evolved rather than disappeared.
In practical terms, the article belongs to the period when laboratory medicine was teaching cardiology how to see injury that the eye could not see. The consequences were immediate at the bedside, but the tools were still crude.
Historical Relevance for Modern Cardiology
Modern practice no longer depends on AST or LDH to diagnose myocardial infarction, yet the conceptual structure established by early enzyme studies remains familiar. Clinicians still look for biomarkers that reflect tissue injury, still depend on serial measurement, and still interpret blood tests alongside symptoms, electrocardiography, and imaging. The difference is specificity. Contemporary cardiac care uses markers designed for the myocardium itself, while the 1963 framework relied on enzymes that signaled damage more broadly.
That historical progression matters because it explains how cardiology arrived at its current diagnostic standards. Each older assay contributed evidence that circulating molecules could reveal internal injury. Each imperfect enzyme test exposed the need for greater specificity. The modern biomarker era did not emerge suddenly; it was built from studies like this one, where clinicians tested the limits of serum chemistry in a disease that often announced itself late and unpredictably.
Martin’s article therefore reads as part diagnostic review, part milestone in laboratory cardiology. It captures a moment when ischemic heart disease was becoming legible in blood chemistry, even though the language of the test was still broad and nonspecific. The clinical challenge it describes remains recognizable: identifying myocardial injury early enough to matter, without mistaking every abnormal enzyme for coronary disease.